Since checkpoint inhibitors primarily act on T cells by ”removing the breaks” that prevent their full function, patients without sufficient tumor-specific CD4+ and CD8+ T cells would be unable to benefit from most checkpoint inhibitor therapies. The gene discussed is CD8A; the disease is neoplasm.